Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by atai Life Sciences
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
April 24, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
April 17, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
March 28, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
March 27, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
March 04, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
February 06, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
January 04, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
January 02, 2024
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
November 14, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
October 06, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
October 02, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 14, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences to Participate in Upcoming September Investor Conferences
September 06, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
August 10, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
August 08, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences to Participate in Upcoming June Investor Conferences
June 01, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
May 11, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences to Participate in Upcoming May Investor Conference
May 02, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
April 28, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
April 13, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
March 24, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
March 06, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
January 09, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 06, 2023
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
December 23, 2022
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
December 19, 2022
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
December 16, 2022
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
November 29, 2022
From
atai Life Sciences
Via
GlobeNewswire
Tickers
ATAI
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.